NicOx’s Partner Bausch + Lomb Initiates Phase 2b Study With Glaucoma Drug-candidate BOL-303259-X (NCX 116)
NicOx S.A. (NYSE Euronext Paris: COX) today announced that its partner Bausch + Lomb has initiated a phase 2b clinical study with BOL-303259-X, previously known as NCX 116. BOL-303259-X is a nitric oxide-donating prostaglandin F2-alpha analog, which lowers intraocular pressure through a dual mechanism of action...